Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9706040 | 0.81 | NPSR1 (0.33) | NPSR1FAAHNAAAGFERRAB9A | |
| SCHEMBL7922674 | 0.81 | NPSR1 (0.34) | NPSR1FAAHNAAARAB9AKMT2A | |
| SCHEMBL11637411 | 0.79 | NPSR1 (0.33) | NPSR1FAAHNAAAALDH1A1POLB | |
| SCHEMBL14866137 | 0.79 | L3MBTL1 (0.36) | NPSR1FAAHNAAARAB9AL3MBTL1 | |
| SCHEMBL20125203 | 0.79 | ALDH1A1 (0.34) | NPSR1FAAHNAAARAB9AKMT2A | |
| SCHEMBL9672935 | 0.74 | GAA (0.38) | RAB9ANPC1L3MBTL1KMT2AMEN1 | |
| SCHEMBL11533645 | 0.73 | — | — | |
| SCHEMBL13103991 | 0.73 | — | — | |
| SCHEMBL9545716 | 0.70 | — | — | |
| SCHEMBL11772103 | 0.69 | KLK5 (0.40) | L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021127188-A1 | ISOXAZOLINE DERIVATIVES AS PESTICIDES | ELANCO TIERGESUNDHEIT AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-9527866-B2 | Processes for production of intermediates for 2-alkyl cephem compounds | SHIONOGI & CO., LTD. (JP) | 2016-12-27 | — | — | US | disclosed |
| US-9334289-B2 | Cephem compound having catechol or pseudo-catechol structure | SHIONOGI & CO., LTD. (JP) | 2016-05-10 | — | — | US | disclosed |
| US-9242999-B2 | Cephem compound having pyridinium group | SHIONOGI & CO., LTD. (JP) | 2016-01-26 | — | — | US | disclosed |
| US-20150344502-A1 | CEPHEM COMPOUND | SHIONOGI & CO., LTD. (JP) | 2015-12-03 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20150291619-A1 | PROCESSES FOR PRODUCTION OF INTERMEDIATES FOR 2-ALKYL CEPHEM COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 2015-10-15 | — | — | US | disclosed |
| US-9085589-B2 | Cephem derivative | SHIONOGI & CO., LTD. (JP) | 2015-07-21 | — | — | US | disclosed |
| US-20140114060-A1 | CEPHEM COMPOUND HAVING PYRIDINIUM GROUP | SHIONOGI & CO., LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| US-20140088302-A1 | NOVEL CEPHEM COMPOUND HAVING CATECHOL OR PSEUDO-CATECHOL STRUCTURE | SHIONOGI & CO., LTD. (JP) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088302-A1 | NOVEL CEPHEM COMPOUND HAVING CATECHOL OR PSEUDO-CATECHOL STRUCTURE | COMT, CMBL, CEP170 | NPSR1 4140/4885FAAH 3255/4885NAAA 201/4885 |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | NPSR1 4771/4885FAAH 3039/4885NAAA 64/4885 |
| US-20140114060-A1 | CEPHEM COMPOUND HAVING PYRIDINIUM GROUP | CEP170, PEPD, CMBL | NPSR1 4613/4885FAAH 3283/4885NAAA 81/4885 |
| US-20150291619-A1 | PROCESSES FOR PRODUCTION OF INTERMEDIATES FOR 2-ALKYL CEPHEM COMPOUNDS | SQOR, DHPS, NISCH | NPSR1 4571/4885FAAH 4105/4885NAAA 1002/4885 |
| US-20150344502-A1 | CEPHEM COMPOUND | PRMT6, CEP170, NR0B1 | NPSR1 1706/4885FAAH 3942/4885NAAA 1415/4885 |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | CEP170, ABL1, CEPT1 | NPSR1 4144/4885FAAH 1876/4885NAAA 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.